News | August 27, 2021
SEC recommends Phase I clinical trials for Reliance’s Covid-19 vaccine candidate
The company has to approach the DCGI for approval to commence the trials
The company has to approach the DCGI for approval to commence the trials
In H1FY21, it attracted PE deals worth US $ 1.6 billion compared to US $ 3 billion in CY2020
The boy becomes India’s youngest recipient to undergo bilateral lung transplantation.
The company to receive upfront and milestone payments, in addition to royalties
The two-year donation supports the development of clinical tests for Covid-19 severity assessment and the focus on the development of simple immunoassays using single molecule counting technology
Opaganib, a leading novel small molecule investigational oral pill in development for Covid-19, is a unique host targeted, dual antiviral and anti-inflammatory drug that acts on the cause and effect of the disease
Goal of providing 12-month internship opportunities for qualified students
CRISIL Ratings has revised its outlook on the long term ratings of Krishna Institute Of Medical Sciences Limited (KIMS) to 'Positive' from 'Stable' while reaffirming the ratings at 'CRISIL AA-/CRISIL A1+'
The aim is to give a fillip to R&D in the health sector to face the Covid-19 challenge
Viraleze was developed for application in the nasal cavity to help reduce exposure to respiratory viruses, including SARS-CoV-2. The product is registered for sale in Europe and India, and available online in certain markets
Subscribe To Our Newsletter & Stay Updated
